Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.12.09.21267513: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study was initiated in April 2020 and completed in November 2020 and was approved by the local ethics committee of the Canton of Zurich, Switzerland (BASEC 2020-00787).
Consent: Written informed consent was obtained from all study participants and convalescent plasma donors.
Field Sample Permit: Convalescent plasma collection was performed based on routine plasma collection procedures via plasmapheresis technology, processed and pathogen inactivated using Intercept® technology according to standard operating procedures as approved by Swissmedic (72)Sex as a biological variable SARS-CoV-2 convalescent plasma: Fully recovered male individuals with previous PCR-confirmed SARS-CoV-2 … SciScore for 10.1101/2021.12.09.21267513: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: The study was initiated in April 2020 and completed in November 2020 and was approved by the local ethics committee of the Canton of Zurich, Switzerland (BASEC 2020-00787).
Consent: Written informed consent was obtained from all study participants and convalescent plasma donors.
Field Sample Permit: Convalescent plasma collection was performed based on routine plasma collection procedures via plasmapheresis technology, processed and pathogen inactivated using Intercept® technology according to standard operating procedures as approved by Swissmedic (72)Sex as a biological variable SARS-CoV-2 convalescent plasma: Fully recovered male individuals with previous PCR-confirmed SARS-CoV-2 infection, were recruited through the Zurich blood donation service as convalescent plasma donors. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Bound immunoglobulin was detected with phycoerythrin (PE)-labeled detector antibodies for IgG, IgA or IgM. phycoerythrin ( PE)-labeled detector antibodies for IgGsuggested: NoneIgMsuggested: NoneAntibody binding titers were defined by serial plasma dilution and recorded as 50% effective titer concentrations (EC50) using a four-parameter logistic curve (y=Bottom+(Top-Bottom)/(1+10^((logEC50-X)*HillSlope) as described. logEC50-X)*HillSlopesuggested: NoneResults are recorded in U/mL. Values ≥0.80 U/mL are recorded as positive for anti-SARS-CoV-2 S antibodies. anti-SARS-CoV-2 Ssuggested: None: SARS-CoV-2 antibody reactivities are correlated within antibody classes Fig. SARS-CoV-2suggested: NoneExperimental Models: Cell Lines Sentences Resources Particles of the env-inactivated HIV-1 reporter construct pHIV-1NL4-3 ΔEnv-NanoLuc (pHIV-1Nanoluc; provided by P. Bieniasz, Rockefeller University, NY, USA) were pseudotyped with codon optimized, truncated SARS-CoV-2 spike (expression plasmid P_CoV2_Wuhan) by co-expression in HEK 293-T cells. HEK 293-Tsuggested: KCB Cat# KCB 200744YJ, RRID:CVCL_0063)Infection of HT1080/ACE2cl.14 cells (provided by P. Bieniasz, Rockefeller University, NY, USA) with SARS-CoV-2 pseudoparticles was detected by measuring the NanoLuc luciferase reporter activity in cell lysates 48 h post infection using the Nano-Glo Luciferase Assay System (Promega, Fitchburg, WI) and readout on a Perkin Elmer EnVision reader. HT1080/ACE2cl.14suggested: NoneRecombinant DNA Sentences Resources Particles of the env-inactivated HIV-1 reporter construct pHIV-1NL4-3 ΔEnv-NanoLuc (pHIV-1Nanoluc; provided by P. Bieniasz, Rockefeller University, NY, USA) were pseudotyped with codon optimized, truncated SARS-CoV-2 spike (expression plasmid P_CoV2_Wuhan) by co-expression in HEK 293-T cells. pHIV-1NL4-3suggested: NoneSoftware and Algorithms Sentences Resources Plasma neutralization titers causing 50% reduction in viral infectivity (NT50) compared to controls without plasma were calculated by fitting a sigmoid dose–response curve (variable slope) to the RLU data, using GraphPad Prism with constraints (bottom=0, top=100). GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Figures were made using the ggplot2 package (79). ggplot2suggested: (ggplot2, RRID:SCR_014601)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04869072 Completed Convalescent Plasma Therapy - Zurich Protocol Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a protocol registration statement.
Results from scite Reference Check: We found no unreliable references.
-
